Guangdong Raynovent Biotech Co.,Ltd received the ethical approval from The First Affiliated Hospital of Guangzhou Medical University for its phase 2 clinical trial of ZSP1273, a Category 1 drug which is being developed for the prevention and treatment of influenza A and human avian influenza. Principal Investigator of this clinical trial is Academician Nanshan Zhong.

Raynovent received the Certificate of Invention Patent (Hydroxyl purine compounds and applications) issued by IP Australia.

Raynovent received the Certificate of Invention Patent (Hydroxyl purine compounds and applications) issued by Canadian Intellectual Property Office.

Guangdong Zhongsheng Raynovent Biotechnology Co., Ltd. has completed the phase 1 clinical trial of ZSP1273, a Category 1 Drug which is being developed to prevent and treat influenza A and human avian influenza in The First Hospital of Jilin University. Phase 2 clinical trial of the drug will be launched soon.

The China National Medical Products Administration (NMPA) has accepted the Investigational New Drug (IND) application of Category 1 Drug ZSP0678 for Nonalcoholic steatohepatitis (NASH) indication.